Drugs / rMVA-HIV
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00083603 | Sep 2004 → Aug 2007 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00107549 | ? → Feb 2009 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rMVA-HIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00083603 ↗ |
| Modality | Vaccine | “Recombinant experimental therapeutic vaccine using the modified vaccinia Ankara vector” NCT00107549 ↗ |
| Route | Intramuscular | “rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections” NCT00083603 ↗ |